Shift Workers' Health Behavior Action Program Across Europe (SHAPE)
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Bremen, Germania
- Reclutamento
- Uni Bremen
-
Contatto:
- U. Klink
- Numero di telefono: 0049 421 218 68980
-
Bremerhaven, Germania
- Non ancora reclutamento
- TTZ
-
-
-
-
-
Rotterdam, Olanda
- Reclutamento
- Erasmus Medical Centre
-
Contatto:
- H. Lammers-van der Holst
- Numero di telefono: 0031 10 704 0704
-
Wageningen, Olanda
- Reclutamento
- Wageningen University & Research
-
Contatto:
- M. Mensink
- Numero di telefono: 0031 (0)317 480 100
-
-
-
-
-
Lodz, Polonia
- Non ancora reclutamento
- Lodz
-
Contatto:
- M. Wrzesińska
- Numero di telefono: 0048 42 272 58 13
- Email: prorektor.int@umed.lodz.pl
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Age ≥ 21 years
- Work ≥ 24 hours per week
- Shift work duration > 3 years and currently doing night shifts
- Expected to continue night shiftwork for at least 1 year after inclusion
- On average working ≥ 4 night shifts per month
- Working generally ≥ 2 consecutive night shifts
- In possession of a smartphone and willing to download the study application
Exclusion Criteria:
- Body Mass Index (BMI) < 18.5 or > 40 kg/m2
- Pregnant or lactating
- Chronic diseases with ongoing therapy (e.g. renal failure, active hepatitis, cirrhosis, myocardial infarction, chronic obstructive pulmonary disease and cancer)
- Current or recent use of medications interfering with sleep, including: Central nervous system stimulants (e.g., Ritalin, Adderall, Modafinil or similar); Chronic use of sleep agents (e.g., benzodiazepine, non-hypnotic benzodiaze-pine, first-generation antihistamine, melatonin receptors agonists or similar); Other medications or combinations significantly affecting sleeping patterns
- Recent or ongoing psychotherapy for sleep disorders
- Current or recent use of medications affecting appetite or weight regulation, including: Appetite-enhancing/weight-gain medications (e.g., atypical antipsychotics, cor-ticosteroids such as prednisone, mirtazapine or similar); Appetite-suppressing/weight-loss medications (e.g., CNS stimulants such as Ritalin, Adderall, GLP-1 receptors agonists or similar); Other medications or combinations significantly influencing appetite or body weight
- Participation in another human trial, lifestyle program or weight loss intervention within the past 3 months
- Planned surgical procedure during the study period
- History of or planned bariatric surgery/treatment
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Intervention
Intervention group receives access to the 24-week combined lifestyle intrevention, which includes the mobile intervention app and four interactive workshops.
|
The 24-week lifestyle intervention is structured in four 6-week blocks focusing on sleep and stress management or diet and physical activity.
Lifestyle advice and behavior change techniques are delivered via a mobile application, complemented by workshops.
|
|
Nessun intervento: Control
The control group receives informational brochures with general advice on the four life-style domains, without active behavioral support.
The control group receives access to the combined lifestyle intrevention after the intervention period has ended.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Sleep duration
Lasso di tempo: From enrollment to the end of intervention (24 weeks)
|
Total sleep time (min/24h)
|
From enrollment to the end of intervention (24 weeks)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Body weight
Lasso di tempo: From enrollment to end of intervention (24 weeks)
|
(kg)
|
From enrollment to end of intervention (24 weeks)
|
|
BMI
Lasso di tempo: From enrollment to end of intervention (24 weeks)
|
(kg/m2)
|
From enrollment to end of intervention (24 weeks)
|
|
Objective sleep quality
Lasso di tempo: From enrollment to end of intervention (24 weeks)
|
Wake after sleep onset (min spent awake/main sleep episode), derived from actigraphy data
|
From enrollment to end of intervention (24 weeks)
|
|
Overall diet quality
Lasso di tempo: From enrollment to end of intervention (24 weeks)
|
Diet quality score: Eetscore™, a 55-item FFQ which is scored with the Dutch Healthy Diet 2015-index to evaluate adherence to the Dutch food-based dietary guideline; resulting in a total score between zero (no adherence) and 100 (complete adherence).
|
From enrollment to end of intervention (24 weeks)
|
|
Physical activity level
Lasso di tempo: From enrollment to end of intervention (24 weeks)
|
Light, moderate, vigorous activity (min), Sedentary time (min) as measured with an actigraphy (Motionwatch)
|
From enrollment to end of intervention (24 weeks)
|
|
Perceived stress
Lasso di tempo: From enrollment to end of intervention (24 weeks)
|
Perceived stress score (PSS-10), a 10-item validated questionnaire assessing the extent to which individuals perceive their lives as unpredictable, uncontrollable, and overloaded.
Items are rated on a 5-point Likert scale referring to experiences over the past month; higher score mean more stress.
|
From enrollment to end of intervention (24 weeks)
|
|
Subjective sleep quality (Insomina)
Lasso di tempo: From enrollment to end of intervention (24 weeks)
|
Insomnia severity (0-28): a 7-item self-administered questionnaire validated in shift workers as a proxy for sleep quality.
Items assess the severity of insomnia symptoms, including difficulties with sleep onset, maintenance, and early awakening.
Each item is scored 0-4, with total scores ranging from 0 to 28; higher scores indicate more severe insomnia
|
From enrollment to end of intervention (24 weeks)
|
|
Subjective leep quality (pattern)
Lasso di tempo: [Time Frame: From enrollment to end of intervention (24 weeks)]
|
Shift Work Disorder Questionnaire (SWDQ): a 4-item questionnaire assessing sleep patterns, excessive sleepiness, and functional impairment related to shift work (53).
Each item is scored 1-4, yielding a total score of 4-16, with higher scores reflecting greater symptom severit
|
[Time Frame: From enrollment to end of intervention (24 weeks)]
|
|
Chrono-nutrition patterns
Lasso di tempo: From enrollment to end of intervention (24 weeks)
|
Meal timing, frequency, regularity; using the Chrono nutrition Questionnaire for Shift Workers (CNQ-Shift).
The questionnaire contains 20-23 questions, five questions each for morning, afternoon, and night shifts, three split shifts questions (if applicable), and two questions for work-free days.
|
From enrollment to end of intervention (24 weeks)
|
|
Food preferences
Lasso di tempo: From enrollment to end of intervention (24 weeks)
|
FFPQ (liking/wanting scores): Participants rate "how pleasant it would be to try a bite of this food," using a 100-point visual analogue scale (explicit liking).
A forced choice procedure is then carried used to assess which food participants would "most like to eat now" (implicit wanting).
|
From enrollment to end of intervention (24 weeks)
|
|
Occupational physical activity
Lasso di tempo: From enrollment to end of intervention (24 weeks)
|
OSPAQ (min)
|
From enrollment to end of intervention (24 weeks)
|
|
Work-related sense of coherence
Lasso di tempo: From enrollment to end of intervention (24 weeks)
|
Work-related sense of coherence Work-Soc (5-point Likert scale), a 9-scale assessing individuals' perceived comprehensibility, manageability, and meaningfulness at work.
|
From enrollment to end of intervention (24 weeks)
|
|
Satisfaction With Life
Lasso di tempo: [Time Frame: From enrollment to end of intervention (24 weeks)]
|
Satisfaction With Life Scale (SWLS): a 5-item questionnaire evaluating global life satisfaction (66).
Items are rated on a 7-point scale
|
[Time Frame: From enrollment to end of intervention (24 weeks)]
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Body composition
Lasso di tempo: From enrollment to end of intervention (24 weeks)
|
body Fat percentage (%) measured with bio-impedance analysis (BIA)
|
From enrollment to end of intervention (24 weeks)
|
|
waist to hip circumference
Lasso di tempo: [Time Frame: From enrollment to end of intervention (24 weeks)]
|
ratio of waist and hip circumference (cm/cm)
|
[Time Frame: From enrollment to end of intervention (24 weeks)]
|
|
Behavior assessment
Lasso di tempo: From enrollment to end of intervention (24 weeks)
|
Action planning, Coping planning, Habit formation, Intention.
All items are scored on a either a 5 or 7-point Likert scale ranging from totally disagree to totally agree.
|
From enrollment to end of intervention (24 weeks)
|
|
Stress biomarker
Lasso di tempo: From enrollment to end of intervention (24 weeks)
|
Hair cortisol concentraition (HCC), pg/mg hair
|
From enrollment to end of intervention (24 weeks)
|
|
glucose
Lasso di tempo: [Time Frame: From enrollment to end of intervention (24 weeks)]
|
fasted blood glucose (mM)
|
[Time Frame: From enrollment to end of intervention (24 weeks)]
|
|
Insulin
Lasso di tempo: [Time Frame: From enrollment to end of intervention (24 weeks)]
|
fasted plasma insulin (pmol/L)
|
[Time Frame: From enrollment to end of intervention (24 weeks)]
|
|
blood lipids
Lasso di tempo: [Time Frame: From enrollment to end of intervention (24 weeks)]
|
fasted blood lipids (mmol/L)
|
[Time Frame: From enrollment to end of intervention (24 weeks)]
|
|
blood pressure
Lasso di tempo: [Time Frame: From enrollment to end of intervention (24 weeks)]
|
Diastolic and systolic blood pressure in fasted state (mmHg)
|
[Time Frame: From enrollment to end of intervention (24 weeks)]
|
|
circadian biomarker
Lasso di tempo: [Time Frame: From enrollment to end of intervention (24 weeks)]
|
urinary melatonin (ng/mL)
|
[Time Frame: From enrollment to end of intervention (24 weeks)]
|
|
Participant satisfaction and feasibility
Lasso di tempo: end of intervention (week 24)
|
assessed using a study-specific questionnaire evaluating participants' experiences with the intervention content, delivery, usability, and perceived burden of the intervention
|
end of intervention (week 24)
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- NL-010791
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .